Generic Name and Formulations:
Amoxapine 25mg, 50mg, 100mg, 150mg; tabs.
Indications for Amoxapine:
Depression in patients with neurotic or reactive depressive disorders as well as endogenous and psychotic depressions. Depression accompanied by anxiety or agitation.
Initially 50mg 2–3 times daily; may increase to 100mg 2–3 times daily by the end of the first week. May increase above 300mg/day if dose has been ineffective for a period of at least 2 weeks. Maintenance: when effective dosage established, may give as single dose at bedtime (max 300mg). Elderly: initially 25mg 2–3 times daily; may increase by the end of the first week to 50mg 2–3 times daily. May increase carefully up to 300mg/day if necessary.
Within 14 days of MAOIs. During acute recovery phase following MI.
Monitor for clinical worsening, suicidality, and unusual changes in behavior, esp. during initial few months of treatment and during dose changes. Screen for bipolar disorder prior to initiating therapy. Urinary retention. Angle-closure glaucoma. Increased intraocular pressure. Cardiovascular disorders (monitor closely). Seizure disorders. Discontinue if rash, fever, tardive dyskinesia or neuroleptic malignant syndrome develop. Write ℞ for smallest practical amount. Pregnancy (Cat.C). Nursing mothers.
During or within 5 weeks of fluoxetine. Hyperpyretic crises, severe convulsions, and death with MAOIs (see Contraindications). Potentiates alcohol, barbiturates, other CNS depressants. Paralytic ileus with anticholinergics. Monitor serum levels with CYP450 2D6 inhibitors (eg, quinidine, cimetidine, phenothiazines, propafenone, flecainide, others: see literature). Caution with concomitant electroshock therapy.
Drowsiness, dry mouth, constipation, blurred vision, CNS effects (eg, anxiety, insomnia, restlessness, nervousness, palpitations, tremors, confusion, excitement, nightmares, ataxia, alterations in EEG patterns), edema, rash, elevated prolactin levels, nausea, dizziness, headache, fatigue, weakness, excessive appetite, increased perspiration.
Formerly known under the brand name Asendin.
Tabs 25mg, 50mg, 100mg—100; 150mg—30
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy